Importance and management of low levels of high-density lipoprotein cholesterol in older adults. Part II: Screening and treatment

Geriatrics and Aging

Volumn 7, Issue 4, 2004, Pages 41-49

  Cardenas, Gustavo A ^a   Lavie, Carl J ^a   Milani, Richard V ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Exercise; Fibrates; High density lipoprotein; Niacin; Statins

Indexed keywords

ATORVASTATIN; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS REACTION; DIET THERAPY; DRUG EFFICACY; ESTROGEN THERAPY; EXERCISE; GERIATRIC DISORDER; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; MYOPATHY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 2442486453     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lavie CJ. Lipid na lipoprotein fractions and coronary artery disease. Mayo Clin Proc 1993;68:618-9.
2. Lavie CJ. O'Keefe JH, Blonde L, et al. High-density lipoprotein cholesterol. Recommendations for routine testing and treatment. Postgrad Med 1990;87:36-44, 47, 51.
3. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
4. Milani RV, Lavie CJ. Recommendations for managing patients with low HDL-cholesterol levels. J Myocardial Ischemia 1992;4:27-46.
5. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51.
6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360: 1623-30.
7. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8
9. Tonkin A. High-density lipoprotein cholesterol and treatment guidelines. Am J Cardiol. 2001;88(12A):41N-44N.
10. Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998;339:12-20
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143.
12. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
13. Leon AS, Sanchez O. Meta-analysis of the effects of aerobic exercise training on blood lipids. Circulation 2001;104 (suppl II):II-414-II415. Abstract
14. Lavie CJ, Milani RV. Benefits of cardiac rehabilitation and exercise training programs in elderly coronary patients. AJGC 2001;10:323-7.
15. Lavie CJ, Milani RV, Degruiter H, et al. Effects of cardiac rehabilitation and exercise training programs on levels of high-density lipoprotein (HDL) cholesterol. Circulation 2001; 104:415 (SupplII).
16. Rubinstein A, Burstein R, Lubin F, et al. Lipoprotein profile changes during intense training of Israeli military recruits. Med Sci Sports Exerc 1995;27:480-4.
17. Lavie CJ, Milani RV. Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996;78:1286-9.
18. Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001;21:1226-32.
19. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992;339:1128-30.
20. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982;248:1465-77.
21. Criqui MH, Wallance RB, Heiss G, et al. Cigarette smoking and plasma high-density lipoprotein cholesterol: the lipid research clinics program prevalence study. Circulation 1980; 62 (suppl IV):IV-70-IV-76.
22. Milani RV, Lavie CJ. Prevalence and effects of nonpharmacologic treatment of "isolated" low-HDL cholesterol in patients with coronary artery disease. J Cardiopulmonary Rehabil 1995;15:439-44.
23. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
24. Wakatsuki A, Ikenoue N, Okatani Y, et al. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 2001;37:425-30.
25. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-3.
26. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999;159:1049-57.
27. Grundy SM, Mok HY, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24-36.
28. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994;154:73-82.
29. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000;160:1177-84.
30. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-5.
31. Brown BG, Zhao, XQ, Chait, A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for th prevention of coronary disease (HATS study). N Engl J Med 200;345:1583.
32. van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response:loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
33. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 2000;35:640-6.
34. The Bezafibrate Infarction Prevention (BIP) Study Group. Lipids and lipoproteins in symptomatic coronary heart disease. Circulation 1992;86:839-48.
35. Rubins HB; Robins SJ; Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (VA-HIT). N Engl J Med 1999;341:410-8.
36. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
37. Corbelli JC, Bullano MF, Willey VJ, et al. Effects of gemfibrozil conversion of fenofibrate on lipids in patients on statin therapy. Am J Cardiol 2002;90:1388-91.
38. Kastelein JJP, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000;86:221.
39. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582-7.
40. Davidson M, Ma P, Stein E, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. AJC 2002;89:268-75.